IPO - Profile


We are a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19. Our goal is to become a leader in the emerging field of aging science by delivering life-changing therapies to the growing number of patients in need. To accomplish this goal, we have assembled an experienced and skilled group of industry professionals, scientists, clinicians and key opinion leaders from leading industry and More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$16.75 1,200,000 Positive High 94.04%

Offering Team

  • Legal counsel
  • Reed Smith LLP
  • Auditors
  • Ernst & Young et Autres

Deal Highlights

Deal Tracker

IPO Dates

Filing 10 Feb, 2021

Offer 10 Feb, 2021

Look Ahead

Lock Up Expiry Aug 10, 2021

IPO Terms

Offer Price $16.75
Offer Size 1M

Market Sentiments

Stock Price